Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

Summary

This phase 3 randomised controlled trial, published in The Lancet Respiratory Medicine in 2022, evaluated the intramuscular administration of tixagevimab–cilgavimab, a long-acting monoclonal antibody combination, for early outpatient treatment of COVID-19 against placebo. The TACKLE trial assessed both efficacy in reducing disease progression and hospitalisation, and safety outcomes. As a clinical virology study, this work falls outside the scope of Vitagri's Pulse Brain focus on farming systems, soil health, nutrient density, and food-based human health.

UK applicability

This trial's findings would be directly relevant to United Kingdom COVID-19 treatment guidelines and NHS clinical practice if positive efficacy was demonstrated. However, the record does not align with Vitagri's core remit of agricultural and nutritional science.

Key measures

As suggested by the title: efficacy measures (viral load, hospitalisation, disease progression) and safety measures (adverse events); study design indicates randomisation, double-blinding, and placebo control in a phase 3 trial

Outcomes reported

The study evaluated the efficacy and safety of intramuscular tixagevimab–cilgavimab (a long-acting monoclonal antibody combination) versus placebo for early outpatient treatment of COVID-19. Primary endpoints likely included viral load reduction, hospitalisation rates, disease progression, and adverse events.

Topic tags